AVT03 + Denosumab
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
This is a Phase I Study Conducted in Healthy Volunteers
Conditions
This is a Phase I Study Conducted in Healthy Volunteers
Trial Timeline
Jul 21, 2023 → Apr 15, 2024
NCT ID
NCT05876949About AVT03 + Denosumab
AVT03 + Denosumab is a phase 1 stage product being developed by Alvotech for This is a Phase I Study Conducted in Healthy Volunteers. The current trial status is completed. This product is registered under clinical trial identifier NCT05876949. Target conditions include This is a Phase I Study Conducted in Healthy Volunteers.
What happened to similar drugs?
0 of 1 similar drugs in This is a Phase I Study Conducted in Healthy Volunteers were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
6
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05876949 | Phase 1 | Completed |
| NCT05395091 | Phase 3 | Completed |
Competing Products
3 competing products in This is a Phase I Study Conducted in Healthy Volunteers
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Preladenant + Placebo | Merck | Phase 2 | 27 |
| Preladenant + Placebo + Anticholinergic agents or propanolol + Haloperidol | Merck | Phase 2 | 27 |
| Certolizumab Pegol | UCB | Phase 3 | 40 |